^Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab (页面存档备份,存于互联网档案馆), American Medical Association.
^ 3.03.1EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases. March 2014, 73 (3): 492–509. PMC 4079096. doi:10.1007/s13554-013-0012-y.
^Simponi (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis. www.drugs.com. [2016-05-09]. (原始内容于2011-06-07).
^Golimumab for the treatment of ulcerative colitis. Clinical and Experimental Gastroenterology. 2014-03-12, 7: 53–9. PMC 3958527. PMID 24648749. doi:10.2147/CEG.S48741.